Smith & Nephew/$SNN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Smith & Nephew
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Ticker
$SNN
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
17,349
ISIN
US83175M2052
Website
Smith & Nephew Metrics
BasicAdvanced
$13B
60.81
$0.47
0.63
$0.72
3.13%
Price and volume
Market cap
$13B
Beta
0.63
52-week high
$31.53
52-week low
$23.69
Average daily volume
675K
Dividend rate
$0.72
Financial strength
Current ratio
2.888
Quick ratio
1.215
Long term debt to equity
61.88
Total debt to equity
63.077
Dividend payout ratio (TTM)
79.37%
Interest coverage (TTM)
4.53%
Profitability
EBITDA (TTM)
1,335
Gross margin (TTM)
70.21%
Net profit margin (TTM)
7.09%
Operating margin (TTM)
11.31%
Effective tax rate (TTM)
17.27%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
5.44%
Return on equity (TTM)
7.86%
Valuation
Price to earnings (TTM)
60.809
Price to revenue (TTM)
4.294
Price to book
1.78
Price to tangible book (TTM)
7.76
Price to free cash flow (TTM)
41.172
Free cash flow yield (TTM)
2.43%
Free cash flow per share (TTM)
69.42%
Dividend yield (TTM)
2.52%
Forward dividend yield
3.13%
Growth
Revenue change (TTM)
4.70%
Earnings per share change (TTM)
56.15%
3-year revenue growth (CAGR)
3.69%
10-year revenue growth (CAGR)
2.33%
3-year earnings per share growth (CAGR)
-7.66%
10-year earnings per share growth (CAGR)
-1.68%
10-year dividend per share growth (CAGR)
2.39%
What the Analysts think about Smith & Nephew
Analyst ratings (Buy, Hold, Sell) for Smith & Nephew stock.
Bulls say / Bears say
Smith & Nephew reported a 4.7% revenue increase to $5.81 billion and adjusted earnings per share rising by 1.7% to 84.3 cents, both exceeding analyst forecasts. (ft.com)
The company anticipates 5% revenue growth this year with a trading profit margin between 19-20%. (ft.com)
Smith & Nephew's shares surged by up to 5% following the announcement of improved profit margins and strong demand for elective surgeries. (reuters.com)
Smith & Nephew downgraded its annual revenue growth forecast from 5-6% to 4.5% due to weaker demand in China, leading to a 12% drop in share prices. (reuters.com)
The company's sales in China have been negatively affected by the country's volume-based procurement programme, which favors lower-cost bids. (ft.com)
Smith & Nephew has experienced frequent organizational changes, including three different CEOs and finance directors over five years, contributing to a 40% decrease in stock value during that period. (ft.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
Smith & Nephew Financial Performance
Revenues and expenses
Smith & Nephew Earnings Performance
Company profitability
Smith & Nephew News
AllArticlesVideos
Smith+Nephew and Standard Health partner on first Orthopaedic Ambulatory Surgery Centre in the UK
GlobeNewsWire·2 days ago
New medial stabilized insert for Smith+Nephew's LEGION™ Total Knee System designed to improve kinematics, stability and procedural versatility
GlobeNewsWire·2 weeks ago
Smith+Nephew awarded contract to provide Negative Pressure Wound Therapy systems to the United States Department of Defense
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Smith & Nephew stock?
Smith & Nephew (SNN) has a market cap of $13B as of June 20, 2025.
What is the P/E ratio for Smith & Nephew stock?
The price to earnings (P/E) ratio for Smith & Nephew (SNN) stock is 60.81 as of June 20, 2025.
Does Smith & Nephew stock pay dividends?
Yes, the Smith & Nephew (SNN) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is $0.72 and the yield is 3.13%. Smith & Nephew has a payout ratio of 79.37% on a trailing twelve-month basis.
When is the next Smith & Nephew dividend payment date?
The next Smith & Nephew (SNN) dividend payment date is unconfirmed.
What is the beta indicator for Smith & Nephew?
Smith & Nephew (SNN) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.